Cargando…

Inhaled corticosteroids and FEV(1) decline in chronic obstructive pulmonary disease: a systematic review

Rate of FEV(1) decline in COPD is heterogeneous and the extent to which inhaled corticosteroids (ICS) influence the rate of decline is unclear. The majority of previous reviews have investigated specific ICS and non-ICS inhalers and have consisted of randomised control trials (RCTs), which have spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whittaker, Hannah R., Jarvis, Debbie, Sheikh, Mohamed R., Kiddle, Steven J., Quint, Jennifer K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894275/ https://www.ncbi.nlm.nih.gov/pubmed/31801539 http://dx.doi.org/10.1186/s12931-019-1249-x

Ejemplares similares

Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting
por: Whittaker, Hannah R, et al.
Publicado: (2019)

Accelerated FEV(1) decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients
por: Whittaker, Hannah R., et al.
Publicado: (2021)

Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV(1) Decline in a COPD Population
por: Whittaker, Hannah R, et al.
Publicado: (2021)

Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease
por: Whittaker, Hannah R, et al.
Publicado: (2020)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
por: Park, Ji Won, et al.
Publicado: (2023)

BMI is associated with FEV(1) decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials
por: Sun, Yilan, et al.
Publicado: (2019)

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Obstructive sleep apnoea accelerates FEV(1) decline in asthmatic patients
por: Wang, Tsai-Yu, et al.
Publicado: (2017)

Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis
por: Hinds, David R, et al.
Publicado: (2016)

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?
por: Suissa, Samy
Publicado: (2020)

The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited
por: Calverley, Peter
Publicado: (2021)

Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia
por: Ekbom, Emil, et al.
Publicado: (2019)

Prediction of five-year mortality after COPD diagnosis using primary care records
por: Kiddle, Steven J., et al.
Publicado: (2020)

Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records
por: Whittaker, Hannah, et al.
Publicado: (2023)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Rational use of inhaled corticosteroids for the treatment of COPD
por: Quint, Jennifer K., et al.
Publicado: (2023)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2017)

Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids
por: Irusen, Elvis M., et al.
Publicado: (2020)

Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan
por: Chiu, Kai-Lin, et al.
Publicado: (2021)

Cut-off value of FEV(1)/FEV(6) to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease
por: Hwang, Yong Il, et al.
Publicado: (2021)

Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?
por: AI-Kassimi, Faisal A., et al.
Publicado: (2013)

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease
por: D’Urzo, Anthony, et al.
Publicado: (2015)

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
por: Hirano, Ryosuke, et al.
Publicado: (2018)

Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects
por: Singh, Dave
Publicado: (2020)

Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
por: Eklöf, Josefin, et al.
Publicado: (2022)

Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease
por: Mohsin, Raza Ul, et al.
Publicado: (2022)

Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis
por: Axson, Eleanor L, et al.
Publicado: (2020)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review
por: Sonnex, Kimberley, et al.
Publicado: (2020)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

Annual change in FEV(1) in elderly 10-year survivors with established chronic obstructive pulmonary disease
por: Suzuki, Masaru, et al.
Publicado: (2019)

Association between annual change in FEV(1) and comorbidities or impulse oscillometry in chronic obstructive pulmonary disease
por: Sugawara, Hiroyuki, et al.
Publicado: (2022)

Rapid FEV(1)/FVC Decline Is Related With Incidence of Obstructive Lung Disease and Mortality in General Population
por: Choi, Kwang Yong, et al.
Publicado: (2022)

Cut-off value of FEV(1)/FEV(6) as a surrogate for FEV(1)/FVC for detecting airway obstruction in a Korean population
por: Chung, Kyung Soo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_94svnbqer5pu7qmtod8ptjir7f